MRA Advisory Group Has $331,000 Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

MRA Advisory Group cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 56.0% in the second quarter, Holdings Channel.com reports. The firm owned 745 shares of the medical equipment provider’s stock after selling 947 shares during the quarter. MRA Advisory Group’s holdings in Intuitive Surgical were worth $331,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in ISRG. Gilbert & Cook Inc. raised its position in Intuitive Surgical by 6.5% in the 4th quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after buying an additional 211 shares during the last quarter. Wealthspire Advisors LLC lifted its position in shares of Intuitive Surgical by 29.8% in the fourth quarter. Wealthspire Advisors LLC now owns 1,259 shares of the medical equipment provider’s stock worth $425,000 after purchasing an additional 289 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its position in shares of Intuitive Surgical by 172.4% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 779 shares of the medical equipment provider’s stock worth $263,000 after purchasing an additional 493 shares in the last quarter. Johnson Investment Counsel Inc. grew its position in Intuitive Surgical by 1.3% in the fourth quarter. Johnson Investment Counsel Inc. now owns 25,368 shares of the medical equipment provider’s stock valued at $8,558,000 after purchasing an additional 334 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its position in Intuitive Surgical by 57.7% in the fourth quarter. JFS Wealth Advisors LLC now owns 175 shares of the medical equipment provider’s stock valued at $59,000 after purchasing an additional 64 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several analyst reports. Citigroup raised their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Morgan Stanley boosted their price target on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Stifel Nicolaus boosted their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Finally, Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $446.45.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $471.82 on Friday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $493.97. The company has a market capitalization of $167.35 billion, a PE ratio of 85.17, a price-to-earnings-growth ratio of 5.43 and a beta of 1.39. The company has a fifty day moving average of $458.74 and a 200-day moving average of $418.27.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the previous year, the company posted $1.18 EPS. Intuitive Surgical’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insider Activity

In other news, SVP Henry L. Charlton sold 40,243 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The disclosure for this sale can be found here. Insiders sold 51,656 shares of company stock valued at $24,700,644 over the last quarter. 0.90% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.